GNF 5837 (CAS 1033769-28-6)
See product citations (1)
QUICK LINKS
GNF 5837 is widely utilized in molecular biology research, particularly in the study of kinase activity and signaling pathways. This compound acts as an inhibitor of specific kinases, making it useful for scientists investigating the regulation of these enzymes in cellular processes. Research involving GNF 5837 primarily focuses on its ability to modulate signaling pathways that are critical for cell growth and survival. By understanding how GNF 5837 influences these pathways, researchers can gain insights into the mechanisms of cell regulation and disease progression. Additionally, GNF 5837 is used in studies aimed at identifying potential targets for new research compounds, providing a foundational approach for further investigations into cellular function and interaction.
GNF 5837 (CAS 1033769-28-6) References
- Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models. | Albaugh, P., et al. 2012. ACS Med Chem Lett. 3: 140-5. PMID: 24900443
- The Complement System Component C5a Produces Thermal Hyperalgesia via Macrophage-to-Nociceptor Signaling That Requires NGF and TRPV1. | Shutov, LP., et al. 2016. J Neurosci. 36: 5055-70. PMID: 27147658
- Albumin hybrid nanoparticles loaded with tyrosine kinase A inhibitor GNF-5837 for targeted inhibition of breast cancer cell growth and invasion. | Shargh, VH., et al. 2016. Int J Pharm. 515: 527-534. PMID: 27793712
- Gelatin-albumin hybrid nanoparticles as matrix metalloproteinases-degradable delivery systems for breast cancer therapy. | Shargh, VH., et al. 2017. Nanomedicine (Lond). 12: 977-989. PMID: 28440712
- Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors. | Aristizabal Prada, ET., et al. 2018. Endocr Relat Cancer. 25: 547-560. PMID: 29563190
- Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer. | Kimura, S., et al. 2018. Lung Cancer. 120: 98-107. PMID: 29748024
- Role of NGF-TrkA signaling in calcification of articular chondrocytes. | Jiang, Y. and Tuan, RS. 2019. FASEB J. 33: 10231-10239. PMID: 31238006
- Trk inhibitor GNF‑5837 suppresses the tumor growth, survival and migration of renal cell carcinoma. | Chen, Y., et al. 2019. Oncol Rep. 42: 2039-2048. PMID: 31485624
- Macrophage-derived neurotrophin-3 promotes heterotopic ossification in rats. | Zhang, J., et al. 2020. Lab Invest. 100: 762-776. PMID: 31896816
- Nerve growth factor and its receptor tyrosine kinase TrkA are overexpressed in cervical squamous cell carcinoma. | Faulkner, S., et al. 2020. FASEB Bioadv. 2: 398-408. PMID: 32676580
- The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer. | Griffin, N., et al. 2020. Biomolecules. 10: PMID: 32957504
- Receptor-Independent Anti-Ferroptotic Activity of TrkB Modulators. | Jakaria, M., et al. 2022. Int J Mol Sci. 23: PMID: 36555849
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GNF 5837, 5 mg | sc-490003 | 5 mg | $81.00 |